(Q35074838)

6 August 2017

1 reference

14 September 2020

Chemotherapy for malignant pleural mesothelioma: past results and recent developments. (English)

1 reference

malignant pleural mesothelioma

6 August 2017

1 reference

14 September 2020

1 reference

3 April 2019

1 reference

1 reference

14 September 2020

1 reference

S Tomek

1

1 reference

6 August 2017

S Emri

series ordinal

2

1 reference

6 August 2017

K Krejcy

series ordinal

3

1 reference

6 August 2017

C Manegold

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

British Journal of Cancer

6 August 2017

27 January 2003

2 references

3 April 2019

14 September 2020

3 references

6 August 2017

3 April 2019

14 September 2020

88

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

167-174

1 reference

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Caelyx in malignant mesothelioma: a phase II EORTC study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

The importance of surgical staging in the treatment of malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A prospective study of detorubicin in malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Benign and malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Phase II trial of vindesine in malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A phase II study of pirarubicin in malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

The role of palliative radiotherapy in malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Malignant mesothelioma: predictors of prognosis and clinical trials

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377054

Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma

27 September 2018

1 reference

12 December 2020

Oral etoposide in the treatment of malignant mesothelioma. A phase II study

1 reference

12 December 2020

Two dose levels of ifosfamide in malignant mesothelioma

1 reference

12 December 2020

Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study

1 reference

12 December 2020

Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma

1 reference

12 December 2020

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force

1 reference

12 December 2020

Phase II study of intravenous Doxil in malignant pleural mesothelioma

1 reference

12 December 2020

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Multimodality therapy for malignant mesothelioma based on a study of natural history

1 reference

12 December 2020

Chemotherapy in the treatment of malignant mesothelioma

1 reference

12 December 2020

High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.

1 reference

12 December 2020

Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study

1 reference

12 December 2020

Vindesine in the treatment of malignant mesothelioma: a phase II study

1 reference

12 December 2020

Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma

1 reference

12 December 2020

Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin

1 reference

12 December 2020

Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma

1 reference

12 December 2020

Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

12 December 2020

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study

1 reference

12 December 2020

Phase II trial of mitomycin in malignant mesothelioma

1 reference

12 December 2020

Technique for external beam treatment for mesothelioma

1 reference

12 December 2020

Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna

1 reference

12 December 2020

Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura

1 reference

12 December 2020

Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study

1 reference

12 December 2020

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

12 December 2020

Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma

1 reference

12 December 2020

Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study

1 reference

12 December 2020

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Phase II trial of topotecan for the treatment of mesothelioma

1 reference

12 December 2020

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile

1 reference

12 December 2020

Ifosfamide in malignant mesothelioma: a phase II study

1 reference

12 December 2020

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study

1 reference

12 December 2020

A phase II study of vincristine in malignant mesothelioma--a negative report

1 reference

12 December 2020

Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors

1 reference

12 December 2020

Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

12 December 2020

Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study

1 reference

12 December 2020

Mitomycin C and Vindesine: An Ineffective Combination Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

1 reference

12 December 2020

Prevention of hepatitis development by interferon-alpha in HBV carriers treated with intensive chemotherapy: a pilot study

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600673

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600673

1 reference

6 August 2017

1 reference

6 August 2017

1 reference